Description
Background:
Sasanlimab, also known as PF-06801591, is a monoclonal antibody that targets the programmed cell death protein 1 (PD-1). PD-1 is a checkpoint protein expressed on certain immune cells, and its activation can dampen immune responses, including the ability to recognize and attack cancer cells. By binding to PD-1, sasanlimab helps to block the interaction between PD-1 and its ligands, such as programmed death-ligand 1 (PD-L1), which are often overexpressed by cancer cells. This blockade can enhance the immune response against cancer cells, allowing the immune system to recognize and attack them more effectively.
Intended Use:
For Estimation of Sasanlimab in human serum and plasma. Please note the kit has not been optimized to be used for any other animal species. Should you require a specific sera tested, please connect with us at sales@krishgen.com for optimization.
If you have published a paper by using any of our ELISA since 01/01/2023, kindly fill out the “Krishgen Publication Reward Application Form” with complete information and send it by at email: info@krishgen.com, with the subject “Krishgen Publication Reward”. We will get back to you with the Amazon / Krishgen Credit Reward after we confirm it ASAP!